These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33141183)

  • 1. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
    Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
    Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes.
    Song X; Wan X; Huang T; Zeng C; Sastry N; Wu B; James CD; Horbinski C; Nakano I; Zhang W; Hu B; Cheng SY
    Cancer Res; 2019 Oct; 79(20):5288-5301. PubMed ID: 31462429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
    Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
    J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin Receptor Splicing Variant
    Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Peel A; Blanco-Acevedo C; Solivera J; Ibáñez-Costa A; Gahete MD; Castaño JP; Luque RM
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB.
    Barbagallo D; Caponnetto A; Cirnigliaro M; Brex D; Barbagallo C; D'Angeli F; Morrone A; Caltabiano R; Barbagallo GM; Ragusa M; Di Pietro C; Hansen TB; Purrello M
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29415469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-1908-5p contributes to the oncogenic function of the splicing factor SRSF3.
    Kim HR; Shin CH; Lee H; Choi KH; Nam DH; Ohn T; Kim HH
    Oncotarget; 2017 Jan; 8(5):8342-8355. PubMed ID: 28039456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes.
    Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Sáez-Martínez P; Fuentes-Fayos AC; Closa A; González-Serrano T; Martínez-López A; Sánchez-Sánchez R; López-Casas PP; Sarmento-Cabral A; Olmos D; Eyras E; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2023 Mar; 253():68-79. PubMed ID: 36089245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidence.
    Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Montero-Hidalgo AJ; Martín-Colom J; Doval-Rosa C; Blanco-Acevedo C; Torres E; Toledano-Delgado Á; Sánchez-Sánchez R; Peralbo-Santaella E; Ortega-Salas RM; Jiménez-Vacas JM; Tena-Sempere M; López M; Castaño JP; Gahete MD; Solivera J; Luque RM
    EBioMedicine; 2023 Apr; 90():104484. PubMed ID: 36907105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splicing factor SRSF3 promotes the progression of cervical cancer through regulating DDX5.
    Che Y; Bai M; Lu K; Fu L
    Mol Carcinog; 2023 Feb; 62(2):210-223. PubMed ID: 36282044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRSF3/AMOTL1 splicing axis promotes the tumorigenesis of nasopharyngeal carcinoma through regulating the nucleus translocation of YAP1.
    Xu XC; Jiang JX; Zhou YQ; He S; Liu Y; Li YQ; Wei PP; Bei JX; Sun J; Luo CL
    Cell Death Dis; 2023 Aug; 14(8):511. PubMed ID: 37558679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SRSF5 functions as a novel oncogenic splicing factor and is upregulated by oncogene SRSF3 in oral squamous cell carcinoma.
    Yang S; Jia R; Bian Z
    Biochim Biophys Acta Mol Cell Res; 2018 Sep; 1865(9):1161-1172. PubMed ID: 29857020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation.
    Jia R; Ajiro M; Yu L; McCoy P; Zheng ZM
    RNA; 2019 May; 25(5):630-644. PubMed ID: 30796096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.
    Aldave G; Gonzalez-Huarriz M; Rubio A; Romero JP; Ravi D; Miñana B; Cuadrado-Tejedor M; García-Osta A; Verhaak R; Xipell E; Martinez-Vélez N; de la Rocha AA; Puigdelloses M; García-Moure M; Marigil M; Gállego Pérez-Larraya J; Marín-Bejar O; Huarte M; Carro MS; Ferrarese R; Belda-Iniesta C; Ayuso A; Prat-Acín R; Pastor F; Díez-Valle R; Tejada S; Alonso MM
    Neuro Oncol; 2018 Jun; 20(7):930-941. PubMed ID: 29373718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways.
    Mu N; Gu J; Liu N; Xue X; Shu Z; Zhang K; Huang T; Chu C; Zhang W; Gong L; Zhao H; Jia B; Gao D; Shang L; Zhang W; Guo Q
    Theranostics; 2018; 8(6):1527-1539. PubMed ID: 29556339
    [No Abstract]   [Full Text] [Related]  

  • 16. HnRNP L is important for the expression of oncogene SRSF3 and oncogenic potential of oral squamous cell carcinoma cells.
    Jia R; Zhang S; Liu M; Zhang Y; Liu Y; Fan M; Guo J
    Sci Rep; 2016 Nov; 6():35976. PubMed ID: 27808105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins.
    Jiménez M; Urtasun R; Elizalde M; Azkona M; Latasa MU; Uriarte I; Arechederra M; Alignani D; Bárcena-Varela M; Álvarez-Sola G; Colyn L; Santamaría E; Sangro B; Rodriguez-Ortigosa C; Fernández-Barrena MG; Ávila MA; Berasain C
    Nucleic Acids Res; 2019 Apr; 47(7):3450-3466. PubMed ID: 30657957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serine/arginine-rich splicing factor 3 (SRSF3) regulates homologous recombination-mediated DNA repair.
    He X; Zhang P
    Mol Cancer; 2015 Aug; 14():158. PubMed ID: 26282282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic SRSF3 in health and diseases.
    Jia R; Zheng ZM
    Int J Biol Sci; 2023; 19(10):3057-3076. PubMed ID: 37416784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SRSF3-MBNL1-Acin1 circuit constitutes an emerging axis to lessen DNA fragmentation in colorectal cancer via an alternative splicing mechanism.
    Chen YS; Liu CW; Lin YC; Tsai CY; Yang CH; Lin JC
    Neoplasia; 2020 Dec; 22(12):702-713. PubMed ID: 33142236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.